New avenue of research: Antiepileptic drug and estradiol neuroprotection in epilepsy

Recent Patents on CNS Drug Discovery

Volumn 3, Issue 2, 2008, Pages 128-137

  Velíšek, Libor ^a   Velíšková, Jana ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

estradiol; Antiepileptic drug; Neuroprotection; Status epilepticus

Indexed keywords

ANTICONVULSIVE AGENT; DIZOCILPINE; ESTRADIOL; ESTROGEN; FELBAMATE; GABAPENTIN; HISTONE DEACETYLASE INHIBITOR; LAMOTRIGINE; NEUROPEPTIDE Y; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TOPIRAMATE; VALPROIC ACID; ANTIEMETIC AGENT; NEUROPROTECTIVE AGENT;

ANTICONVULSANT ACTIVITY; APOPTOSIS; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; ESTROGEN THERAPY; HORMONE ACTION; HUMAN; LOW DRUG DOSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; ANIMAL;

ANIMALS; ANTIEMETICS; EPILEPSY; ESTROGENS; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 49149126783     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488908784534577     Document Type: Review

References (148)

1. Baulieu E-E, Robel P, Schumacher M, editors. Neurosteroids: A new regulatory function in the nervous system. Totowa: Humana Press; 1999.
2. Pitkanen A, Kubova H. Antiepileptic drugs in neuroprotection. Expert Opin Pharmacother 2004; 5: 777-798.
3. Lowenstein DH. Status epilepticus: An overview of the clinical problem. Epilepsia 1999; 40 Suppl 1: S3-8; discussion S21-22.
4. Hauser WA, Lee JR. Do seizures beget seizures? Prog Brain Res 2002; 135: 215-219.
5. Lewis DV, Barboriak DP, MacFall JR, et al. Do prolonged febrile seizures produce medial temporal sclerosis? Hypotheses, MRI evidence and unanswered questions. Prog Brain Res 2002; 135: 263-278.
6. Haut SR. Velíšková J, Moshe SL. Susceptibility of immature and adult brains to seizure effects. Lancet Neurol 2004; 3: 608-617.
7. Brandt C, Potschka H, Loscher W, Ebert U. N-methyl-D-aspartate receptor blockade after status epilepticus protects against limbic brain damage but not against epilepsy in the kainate model of temporal lobe epilepsy. Neuroscience 2003; 118: 727-740.
8. Hoffman GE, Moore N, Fiskum G, Murphy AZ. Ovarian steroid modulation of seizure severity and hippocampal cell death after kainic acid treatment. Exp Neurol 2003; 182: 124-134.
9. Stein DG, Wright DW, Kellermann AL. Does progesterone have neuroprotective properties? Ann Emerg Med 2008; 51: 164-172.
10. Wright DW, Hoffman SW, Virmani S, Stein DG. Effects of medroxyprogesterone acetate on cerebral oedema and spatial learning performance after traumatic brain injury in rats. Brain Inj 2008; 22: 107-113.
11. Brandt C, Gastens AM, Sun M, Hausknecht M, Loscher W. Treatment with valproate after status epilepticus: Effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 2006; 51: 789-804.
12. Kozachuk, W.E.: US20036515019 (2003).
13. Macdonald, T.L.: US20036599935 (2003).
14. Kito M, Maehara M, Watanabe K. Antiepileptic drugs - calcium current interaction in cultured human neuroblastoma cells. Seizure 1994; 3: 141-149.
15. Stefani A, Calabresi P, Pisani A, et al. Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J Pharmacol Exp Ther 1996; 277: 121-127.
16. Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000; 41 Suppl 1: S52-60.
17. (2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002; 42: 229-236.
18. Stefani A, Pisani A, De Murtas M, et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 1995; 36: 997-1002.
19. DeLorenzo RJ. Calmodulin in neurotransmitter release and synaptic function. Fed Proc 1982; 41: 2265-2272.
20. Chen PS, Wang CC, Bortner CD, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007; 149: 203-212.
21. Pitkanen A. Drug-mediated neuroprotection and antiepileptogenesis: animal data. Neurology 2002; 59: S27-33.
22. Prasad A, Williamson JM, Bertram EH. Phenobarbital and MK-801, but not phenytoin, improve the long-term outcome of status epilepticus. Ann Neurol 2002; 51: 175-181.
23. Pitkanen A, Nissinen J, Nairismagi J, et al. Progression of neuronal damage after status epilepticus and during spontaneous seizures in a rat model of temporal lobe epilepsy. Prog Brain Res 2002; 135: 67-83.
24. Ebert U, Brandt C, Loscher W. Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. Epilepsia 2002; 43 Suppl 5: 86-95.
25. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: Meta-analysis of controlled trials. Epilepsia 2001; 42: 515-524.
26. Moros, D.A., Levitt, B., Yacobi, A.: US20046756379 (2004).
27. Sulzbacher S, Farwell JR, Temkin N, Lu AS, Hirtz DG. Late cognitive effects of early treatment with phenobarbital. Clin Pediatr (Phila) 1999; 38: 387-394.
28. Simpkins, J.W., Singh, M., Bishop, J.: US5554601 (1996).
29. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 2002; 57: 357-384.
30. Hammes A, Andreassen TK, Spoelgen R, et al. Role of endocytosis in cellular uptake of sex steroids. Cell 2005; 122: 751-762.
31. Hewitt SC, Korach KS. Estrogen receptors: Structure, mechanisms and function. Rev Endocr Metab, Disord 2002; 3: 193-200.
32. Pettersson K, Gustafsson JA. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 2001; 63: 165-192.
33. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002; 16: 70-84.
34. Toran-Allerand CD, Guan X, MacLusky NJ, et al. ER-X: A novel, plasma membrane-associated, putative estrogen receptor that is ragulated during development and after ischemic brain injury. J Neurosci 2002; 22: 8391-8401.
35. Qiu J, Bosch MA, Tobias SC, et al. Rapid signaling of estrogen in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C. J Neurosci 2003; 23: 9529-9540.
36. Qiu J, Ronnekleiv OK, Kelly MJ. Modulation of hypothalamic neuronal activity through a novel G-protein-coupled estrogen membrane receptor. Steroids 2008.
37. Raz L, Khan MM, Mahesh VB, Vadlamudi RK, Brann DW. Rapid estrogen signaling in the brain. Neurosignals 2008; 16: 140-153.
38. Dewing P, Boulware MI, Sinchak K, et al. Membrane estrogen receptor-alpha interactions with metabotropic glutamate receptor 1a modulate female sexual receptivity in rats. J Neurosci 2007; 27: 9294-9300.
39. Makara GB, Haller J. Non-genomic effects of glucocorticoids in the neural system. Evidence, mechanisms and implications. Prog Neurobiol 2001; 65: 367-390.
40. Pfaff D, Keiner M. Atlas of estradiol-concentrating cells in the central nervous system of the female rat. J Comp Neurol 1973; 151: 121-158.
41. Mufson EJ, Cai WJ, Jaffar S, et al. Estrogen receptor immunoreactivity within subregions of the rat forebrain: Neuronal distribution and association with perikarya containing choline acetyltransferase. Brain Res 1999; 849: 253-274.
42. Zhang JQ, Cai WQ, Zhou de S, Su BY. Distribution and differences of estrogen receptor beta immunoreactivity in the brain of adult male and female rats. Brain Res 2002; 935: 73-80.
43. Mitra SW, Hoskin E, Yudkovitz J, et al. Immunolocalization of estrogen receptor beta in the mouse brain: Comparison with estrogen receptor alpha. Endocrinology 2003; 144: 2055-2067.
44. Shughrue PJ, Scrimo PJ, Merchenthaler I. Estrogen binding and estrogen receptor characterization (ERalpha and ERbeta) in the cholinergic neurons of the rat basal forebrain. Neuroscience 2000; 96: 41-49.
45. Toran-Allerand CD, Miranda RC, Bentham WD, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1992; 89: 4668-4672.
46. Gritti I, Mainville L, Jones BE. Codistribution of GABA- with acetylcholine-synthesizing neurons in the basal forebrain of the rat. J Comp Neurol 1993; 329: 438-457.
47. Leranth C, Shanabrough M, Horvath TL. Estrogen receptor-alpha in the raphe serotonergic and supramammillary area calretinin-containing neurons of the female rat. Exp Brain Res 1999; 128: 417-420.
48. Weiland NG, Orikasa C, Hayashi S, McEwen BS. Distribution and hormone regulation of estrogen receptor immunoreactive cells in the hippocampus of male and female rats. J Comp Neurol 1997; 388: 603-612.
49. Azcoitia I, Sierra A, Garcia-Segura LM. Localization of estrogen receptor beta-immunoreactivity in astrocytes of the adult rat brain. Glia 1999; 26: 260-267.
50. Kalita K, Szymczak S, Kaczmarek L. Non-nuclear estrogen receptor beta and alpha in the hippocampus of male and female rats. Hippocampus 2005; 15: 404-412.
51. Milner TA, Ayoola K, Drake CT, et al. Ultrastructural localization of estrogen receptor beta immunoreactivity in the rat hippocampal formation. J Comp Neurol 2005; 491: 81-95.
52. Mukai H, Tsurugizawa T, Murakami G, et al. Rapid modulation of long-term depression and spinogenesis via synaptic estrogen receptors in hippocampal principal neurons. J Neurochem 2007; 100: 950-967.
53. Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. Stroke 1996; 27: 1479-1486.
54. Henderson VW. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 1997; 48: S27-35.
55. Birge SJ, McEwen BS, Wise PM. Effects of estrogen deficiency on brain function. Implications for the treatment of postmenopausal women. Postgrad Med 2001; Spec No: 11-16.
56. Suzuki S, Brown CM, Wise PM. Mechanisms of neuroprotection by estrogen. Endocrine 2006; 29: 209-215.
57. Yang SH, Shi J, Day AL, Simpkins JW, Robinson SE. Estradiol exerts neuroprotective effects when administered after ischemic insult [In Process Citation]. Stroke 2000; 31: 745-750.
58. Azcoitia I, Sierra A, Garcia-Segura LM. Estradiol prevents kainic acid-induced neuronal loss in the rat dentate gyms. Neuroreport 1998; 9: 3075-3079.
59. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem 1996; 66: 1836-1844.
60. Gridley KE, Green PS, Simpkins JW. Low concentrations of estradiol reduce beta-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res 1997; 778: 158-165.
61. Vedder H, Anthes N, Stumm G, et al. Estrogen hormones reduce lipid peroxidation in cells and tissues of the central nervous system. J Neurochem 1999; 72: 2531-2538.
62. Singer CA, Figueroa-Masot XA, Batchelor RH, Dorsa DM. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci 1999; 19: 2455-2463.
63. Shi J, Simpkins JW. 17 beta-Estradiol modulation of glucose transporter 1 expression in blood-brain barrier. Am J Physiol 1997; 272: E1016-1022.
64. Josefsson E, Tarkowski A, Carlsten H. Anti-inflammatory properties of estrogen. I. in vivo Suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. Cell Immunol 1992; 142: 67-78.
65. Nilsen J, Diaz BR. Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. Proc Natl Acad Sci USA 2003; 100: 2842-2847.
66. Nilsen J, Mor G, Naftolia F. Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol 2000; 43: 64-78.
67. Garcia-Segura LM, Cardona-Gomez P, Naftolin F, Chowen JA. Estradiol upregulates Bcl-2 expression in adult brain neurons. Neuroreport 1998; 9: 593-597.
68. Pike CJ. Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: Relevance to Alzheimer's disease. J Neurochem 1999; 72: 1552-1563.
69. Simpkins, J.W., Covey, D.F.: US20026350739 (2002).
70. Voskuhl, R.R.: US20056936599 (2005).
71. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology 2000; 54: 295-301.
72. Waring SC, Rocca WA, Petersen RC, et al. Postmenopausal estrogen replacement therapy and risk of AD: A population-based study. Neurology 1999; 52: 965-970.
73. Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998; 50: 1141-1143.
74. Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000; 54: 2292-2298.
75. Paganini-Hill A. Estrogen replacement therapy and stroke. Prog Cardiovasc Dis 1995; 38: 223-242.
76. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausa] women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
77. Tsang TS, Barnes ME, Gersh BJ, Hayes SN. Risks of coronary heart disease in women: Current understanding and evolving concepts. Mayo Clin Proc 2000; 75: 1289-1303.
78. Scanlan, T.S., Kelly, M.J., Qiu, J., Tobias, S., Ronnekleiv, O.K.: US20077196119 (2007).
79. Gowers WR. Epilepsy and other chronic convulsive diseases. London: J.A. Churchill; 1881.
80. Locock C. Discussion of paper by EH Sieveking. Analysis of 52 cases of epilepsy observed by the author. Lancet 1857; 1: 527-528.
81. Laidlaw J. Catamenial epilepsy. Lancet 1956; 2: 1235-1237.
82. Logothetis J, Harner R, Morrel F, Torres F. The role of estrogens in catamenial exacerbation of epilepsy. Neurology (Minneap) 1959; 9: 352-360.
83. Backstrom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 1976; 54: 321-347.
84. Herzog AG, Harden CL, Liporace J, et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol 2004; 56: 431-434.
85. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997; 38: 1082-1088.
86. Harden CL, Pulver MC, Ravdin L, Jacobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999; 40: 1402-1407.
87. Bickerstaff E. Neurological complications of oral contraceptives. Oxford: Clarendon Press; 1975.
88. Marcus E, Watson C, DeLuca A. Factors influencing the epileptogenic effects of conjugated equine estrogens (Premarin) on cerebral electrical activity in cat and man. Electroenceph Clin Neurophysiol 1963; 15: 150-151.
89. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA 1986; 256: 238-240.
90. Sanchez LLP, Gonzalez SLE. Hormones and their influence in epilepsy. Acta Neurol Latinoam 1966; 12: 29-47.
91. Woolley DE, Timiras PS. Gonad-brain relationship: Effects of castration and testosterone on electroshock convulsions in male rats. Endocrinology 1962; 71: 609-617.
92. Woolley DE, Timiras PS, Woodbury DM. Same effects of sex steroids on brain excitability and metabolism. Proc West Pharmacol Soc 1960; 3: 11-23.
93. Hom AC, Buterbaugh GG. Estrogen alters the acquisition of seizures kindled by repeated amygdala stimulations or pentylene-tetrazol administration in ovariectomized female rats. Epilepsia 1986; 27: 103-108.
94. Edwards HE, Burnham WM, Mendonca A, Bowlby DA, MacLusky NJ. Steroid hormones affect limbic after discharge thresholds and kindling rates in adult female rats. Brain Res 1999; 838: 136-150.
95. Woolley DE, Timiras PS. Estrous and circadian periodicity and electroshock convulsions in rats. Am J Physiol 1962; 202: 379-382.
96. Marcus EM, Watson CW, Goldman PL. Effects of steroids on cerebral electrical activity. Epileptogenic effects of conjugated estrogens and related compounds in the cat and rabbit. Arch Neurol 1966; 15: 521-532.
97. Teyler TJ, Vardaris RM, Lewis D, Rawitch AB. Gonadal steroids: Effects on excitability of hippocampal pyramidal cells. Science 1980; 209: 1017-1019.
98. Smith CC, McMahon LL. Estradiol-induced increase in the magnitude of long-term potentiation is prevented by blocking NR2B-containing receptors. J Neurosci 2006; 26: 8517-8522.
99. Woolley CS, McEwen BS. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci 1994; 14: 7680-7687.
100. Woolley CS, Weiland NG, McEwen BS, Schwartzkroin PA. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: Correlation with dendritic spine density. J Neurosci 1997; 17: 1848-1859.
101. Woolley CS, Wenzel HJ, Schwartzkroin PA. Estradiol increases the frequency of multiple synapse boutons in the hippocampal CA1 region of the adult female rat. J Compar Neurol 1996; 373: 108-117.
102. Velíšková J, Velíšek L. Beta-estradiol increases dentate gyrus inhibition in female rats via augmentation of hilar neuropeptide Y. J Neurosci 2007; 27: 6054-6063.
103. Velíšek L, Velíšková J, Etgen AM, Stanton PK, Moshé SL. Region-specific modulation of limbic seizure susceptibility by ovarian steroids. Brain Res 1999; 842: 132-138.
104. Velíšková J, Velíšek L, Galanopoulou AS, Sperber EF. Neuroprotective effects of estrogens on hippocampal cells in adult female rats after status epilepticus. Epilepsia 2000; 41: S30-35.
105. Reibel S, Andre V, Chassagnon S, et al. Neuroprotective effects of chronic estradiol benzoate treatment on hippocampal cell loss induced by status epilepticus in the female rat. Neurosci Lett 2000; 281: 79-82.
106. Woolley CS. Estradiol facilitates kainic acid-induced, but not flurothyl-induced, behavioral seizure activity in adult female rats. Epilepsia 2000; 41: 510-515.
107. Nicoletti F, Speciale C, Sortino MA, et al. Comparative effects of estradiol benzoate, the antiestrogen clomiphene citrate, and the progestin medroxyprogesterone acetate on kainic acid-induced seizures in male and female rats. Epilepsia 1985; 26: 252-257.
108. Gevorkyan ES, Nazaryan KB, Kostanyan AA. Modifying effect of estradiol and progesterone on epileptic activity of the rat brain. Neurosci Behav Physiol 1989; 19: 412-415.
109. Buterbaugh GG, Hudson GM. Estradiol replacement to female rats facilitates dorsal hippocampal but not ventral hippocampal kindled seizure acquisition. Exp Neurol 1991; 111: 55-64.
110. Schwartz-Giblin S, Korotzer A, Pfaff DW. Steroid hormone effects on picrotoxin-induced seizures in female and male rats. Brain Res 1989; 476: 240-247.
111. Tominaga K, Yamauchi A, Shuto H, et al. Ovariectomy aggravates convulsions and hippocampal gamma-aminobutyric acid inhibition induced by cyclosporin A in rats. Eur J Pharmacol 2001; 430: 243-249.
112. Kalkbrenner KA, Standley CA. Estrogen modulation of NMDA-induced seizures in ovariectomized and non-ovariectomized rats. Brain Res 2003; 964: 244-249.
113. Dawson R Jr., Wallace DR. Kainic acid-induced seizures in aged rats: neurochemical correlates. Brain Res Bull 1992; 29: 459-468.
114. Galanopoulou AS, Alm EM, Veliskova J. Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats. Neurosci Lett 2003; 342: 201-205.
115. Woolley DE, Timiras PS. The gonad-brain relationship: Effects of female sex hormones on electroshock convulsions in the rat. Endocrinology 1962; 70: 196-209.
116. Engel J Jr., Williamson PD, Wieser H-G. Mesial temporal lobe epilepsy. In: Engel Jr. J, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Lippincot-Raven Publishers; 1997; 2417-2426.
117. Babb TL, Brown WJ. Pathological findings in epilepsy. In: Engel JJ, ed. Surgical treatment of the epilepsies. Raven Press 1987; 511-540.
118. Ounsted C, Lindsay J, Richards P. Temporal Lobe Epilepsy: A Biographical Study 1948-1986. Oxford: MacKeith Press; 1987.
119. Briellmann RS, Berkovic SF, Jackson GD. Men may be more vulnerable to seizure-associated brain damage. Neurology 2000; 55: 1479-1485.
120. Herzog AG. Intermittent progesterone therapy and frequency of complex partial seizures in women with menstrual disorders. Neurology 1986; 36: 1607-1610.
121. Morrell MJ. Hormones, Reproductive Health, and Epilepsy. In: Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice. 2nd ed. Williams & Wilkins; 1997; 179-187.
122. Mathern GW, Babb TL, Armstrong DL. Hippocampal sclerosis. In: Engel JJ, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Lippincott-Raven; 1997; 133-155.
123. de Lanerolle NC, Kim JH, Robbins RJ, Spencer DD. Hippocampus interneuron loss and plasticity in human temporal lobe epilepsy. Brain Res 1989; 495: 387-395.
124. Sutula T, Cascino G, Cavazos J, Parada I, Ramirez L. Mossy fiber synaptic reorganization in the epileptic human temporal lobe. Ann Neurol 1989; 26: 321-330.
125. Sloviter RS. The functional organization of the hippocampal dentate gyrus and its relevance to the pathogenesis of temporal lobe epilepsy. Ann Neurol 1994; 35: 640-654.
126. Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: Mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985; 14: 375-403.
127. Turski L, Cavalheiro EA, Sicklucka-Dziuba M, et al. Seizures produced by pilocarpine: Neuropathological sequelae and activity of glutamate decarboxylase in the rat forebrain. Brain Res 1986; 398: 37-48.
128. Nadler JV. Minireview. Kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci 1981; 29: 2031-2042.
129. Azcoitia I, Sierra A, Garcia-Segura LM. Neuroprotective effects of estradiol in the adult rat hippocampus: Interaction with insulin-like growth factor-I signalling. J Neurosci Res 1999; 58: 815-822.
130. Vezzani A, Sperk G, Colmers WF. Neuropeptide Y: Emerging evidence for a functional role in seizure modulation. Trends Neurosci 1999; 22: 25-30.
131. El Bahh B, Auvergne R, Lere C, et al. Decreased epileptic susceptibility correlates with neuropeptide Y overexpression in a model of tolerance to excitotoxicity. Brain Res 2001; 894: 209-217.
132. Silva AP, Carvalho AP, Carvalho CM, Malva JO. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus. Neuropharmacology 2003; 44: 282-292.
133. Sloviter RS, Lowenstein DH. Heat shock protein expression in vulnerable cells of the rat hippocampus as an indicator of excitation-induced neuronal stress. J Neurosci 1992; 12: 3004-3009.
134. Freund TF, Buzsaki G. Interneurons of the hippocampus. Hippocampus 1996; 6: 347-470.
135. Velísěk L, Velíšková J. Estrogen treatment protects GABA(B) inhibition in the dentate gyrus of female rats after kainic acid-induced status epilepticus. Epilepsia 2002; 43 Suppl 5: 146-151.
136. Velíšková J. The role of estrogens in seizures and epilepsy: The bad guys or the good guys? Neuroscience 2006; 138: 837-844.
137. Velíšková J. Estrogens and epilepsy: Why are we so excited? Neuroscientist 2007; 13: 77-88.
138. Murphy S, McCullough L, Littleton-Kearney M, Hurn P. Estrogen and selective estrogen receptor modulators: Neuroprotection in the Women's Health Initiative era. Endocrine 2003; 21: 17-26.
139. Yalcin A, Kanit L, Durmaz G, et al. Altered level of apurinic/ apyrimidinic endonuclease/redox factor-1 (APE/REF-1) mRNA in the hippocampus of ovariectomized rats treated by raloxifene against kainic acid. Clin Exp Pharmacol Physiol 2005; 32: 611-614.
140. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 2003; 289: 2673-2684.
141. Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog Neurobiol 2001; 63: 29-60.
142. Wise PM. Estrogens and neuroprotection. Trends Endocrinol Metab 2002; 13: 229-230.
143. Bolton JL, Pisha E, Zhang F, Qiu S. Role of quinoids in estrogen carcinogenesis. Chem Res Toxicol 1998; 11: 1113-1127.
144. Marsden J. The menopause, hormone replacement therapy and breast cancer. J Steroid Biochem Mol Biol 2002; 83: 123-132.
145. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003; 97: 1387-1392.
146. Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection: Synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 2002; 143: 205-212.
147. Utian WH. NIH and WHI: Time for a mea culpa and steps beyond. Menopause 2007; 14: 1056-1059.
148. Studd J. Variations on hormone replacement therapy: An answer to the 'one dose fits all' Women's Health initiative study. Gynecol Endocrinol 2007; 23: 665-671.